Vesigenurtucel-L

Drug Profile

Vesigenurtucel-L

Alternative Names: HS-410; UM-UC-3-gp96-Ig-HLA-A1; vesigenurtacel-L

Latest Information Update: 10 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator University of Miami
  • Developer Heat Biologics
  • Class Adjuvants; Cancer vaccines; Cell therapies; Heat shock proteins; Tumour cell vaccines
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Bladder cancer

Most Recent Events

  • 05 Jun 2017 Additional efficacy data from a phase II trial in Bladder cancer released by Heat Biologics
  • 11 May 2017 Discontinued - Phase-II for Bladder cancer (Monotherapy, Adjuvant therapy) in USA (Intradermal)
  • 11 May 2017 Heat Biologics terminated a phase II trial in Bladder cancer (Monotherapy, Adjuvant therapy) in USA due to change in priority and the company reallocating resources towards combination program (Intradermal) (NCT02010203)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top